1. Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference from the American Diabetes Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24.
2. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100mg/dl. Am J Cardiol 2006 Dec 15;98(12):1599-602.
3. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalization in Get With The Guidelines. Am Heart J. 2009 Jan;157(1):111-117.
4. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 202 Jul 1;22(7)1175-80.
5. Rosenson RS, Otvos JD, Freedman DS. Relationship of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002 Jul 15;90(2):89-94.
6. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006 Mar 28;113(12):1556-63.
7. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007 May;192(1):211-7.
8. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010 Nov;213(1)1-7.
9. Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011 Mar-Apr;5(2):105-13.
10. Suzuki T, Solomon C, Jenny NS, et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail. 2009 Sep;2(5):429-36.
11. Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: a risk marker or risk factor? Am J Cardiol. 2008 Jun 16;101(12A):11F-22F.
12. Brilakis ES, Khera A, Saeed B, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem. 2008 Dec;54(12):1975-81.
13. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoproteinassociated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16;101(12A):41F-50F.
14. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 12;101(12A):51F-57F.
15. Ridker PM, Rifiai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 200 Apr 18;101(15):1767-72.
16. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012 Mar 31;379(9822):1205-13.
17. Nishida H, Horio T, Suzuki Y, et al. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine. 2011 Mar;53(3)342-6.
18. Jug B, Salobir BG, Vene N, et al. Interleukin-6 is a stronger prognostic predictor than high-sensitivity C-reactive protein in patients with chronic stable heart failure. Heart Vessels. 2009 Jul;24(4):271-6.
19. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005 Aug 16;112(7):976-83.
20. Walldius G, Jungner I. Is there a better marker of cardiovascular risk that LDL cholesterol? Apolipoprotiens B and A-1 – new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis. 2007 Oct;17(8):565-71.
21. Walldius G, Jungner I. Apolipoprotein A-1 versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol. 2007 Jul;22(4):359-67.
22. Onat A, Ozhan H, Can G, et al. Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks. Anadolu Kardiyol Derg. 2007 Jun;7(2):128-33.
23. Walldius G, Jungner I. The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med. 2006 May;259(5):493-519.
24. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005 Jul 7;353(1):46-57.
25. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995 Dec 13;274(22):1771-4.
26. Hopkins PN, Wu LL, Hunt SC, et al. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2783-92.
27. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000 Sept 5;102(10):1082-5.
28. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacology & Therapeutics. 2006 July;111(1):18-26.
29. Nicholls SJ, Hazen SL. Myeloperoxidase and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1102-1111.